proteasome


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

proteasome

[′prōd·ē·ə‚sōm]
(biochemistry)
A large proteolytic particle found in the cytoplasm and nucleus of all eukaryotic cells that is the site for degradation of most intracellular proteins.
Mentioned in ?
References in periodicals archive ?
This opens the door for a fully oral proteasome inhibitor-based triplet combination therapy.
Fortunately, scientific evidence indicates that several nutrients can combat the occurrence of damaged proteins and directly activate the proteasome, along with restoring moisture to inhibit cellular skin aging.
In normal young cells, Nrf2 allows continuous regulation of proteasome production in response to changing oxidative environments.
Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance.
Effects of chronic ethanol administration on rat liver proteasome activities: Relationship with oxidative stress.
Proteasome activation induced by high pressure may be involved in the pressure-induced modification or breakdown of muscle proteins (Otsuka et al, 1998; Gardrat et al.
Measurements of proteasome activity were performed by use of the fluorigenic substrate Suc-LLVY-MCA (final concentration, 100 [micro] mol/L) as described elsewhere (7).
A cell marks proteins with this "kiss of death" molecule--itself a small protein--and then shuttles the doomed proteins to its waste-disposal units, called proteasomes.
Millennium says Velcade, the first in a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma, a cancer of the blood.
In addition, each antigen fragment is fused to the ubiquitin protein to increase antigen expression and target these antigens to the proteasome to enhance cytotoxic T lymphocyte (CTL) responses.
While healthy cells appear to be able to recover from the effects of proteasome inhibition, in laboratory studies, cancer cells seem to be more sensitive to its pro-apoptotic effects.
The FDA decision follows the recent approval of KYPROLIS([R]), a second-generation proteasome inhibitor for myeloma patients who have relapsed after previous therapies.

Full browser ?